Aimmune’s Peanut Allergy Drug Desensitizes Patients in TrialCaroline Chen
Aimmune Therapeutics Inc.’s treatment for peanut allergy successfully desensitized patients in a midstage trial. If eventually approved, it would be the first oral drug for the condition.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.